Prostate cancer (PCa), one of the current world’s major health concerns has the highest incidence of any type of cancer. It is the 2nd most common type of cancer and the 5th most frequent cause of cancer-related death in men worldwide. PCa develops after the age of fifty in men. Unfortunately, many patients do not have indications, they don’t take treatment & 2/3rd of cases of PCa grow slowly. High-risk tumour predicts prostate-specific antigen (PSA) levels ≥20ng/mL, stage T3-T4 disease, or Gleason scores ≥7. These characteristics are represented by 20-30% of PCa patients.
Hormone therapy & external beam radiotherapy alone are found to be effective and acceptable methods in locally advanced PCa. Both methods have certain side effects.
• Frequent urge to urinate, dysuria, nocturia & genitourinary irritation
• Enhanced desire to defecate & rectal mucus passage or bleeding
• Raise in risk of development of secondary malignancies in 10-15 years
• Palpitation, hot flashes, headache, tiredness, fatigue & gynecomastia
• Libido loss & erectile dysfunction
• Weight gain or loss of muscle mass
• Mood swings, depression & impaired vision
• Cardiac attack & stroke
Treatment of high-risk PCa is not easy due to its poorer interpretation. One of the chief therapies for enlarged prostrate (>60 mL) is a combination of radiation therapy and hormone therapy.
Neoadjuvant therapy includes hormone therapy, simultaneously adjuvant therapy of percutaneous radiation is provided. Androgen receptor blockers like bicalutamide or gonadotropin-releasing.
hormone & agonists like goserelin or antagonists like degarelix are also prescribed. Hormone therapy sterilizes occult metastases & radiation kills tumor cells irrespective of hormone sensitivity in cumulative cooperation. This unique combination offers 1. Increasing dose allowance with low toxicity offers prostatic volume debulking 2. Enhanced radiosensitivity due to tumor hypoxia reduction 3. Decrease cell repopulation during radiation therapy because of cell cycle slowing 4. Immunomodulation-induced apoptosis and direct effect on tumour cells 5. Supra-additive effect The advantages of combination therapy include better biochemical regulation, up to 50% drop in prostate volume, cancer-specific & relapse-free survival & overall improved survival benefits & lowered cancer reappearance and positive influence on total mortality & disease-specific mortality rate.
Combination therapy of radiation & hormone therapy in PCa requires more focused clinical trials in order to make it more suitable & usable. Simultaneously detailed patient investigation records including the onset of PCa, evolution, statin intake, diet habits & patterns, daily lifestyle, weight & body mass index, smoking and PCa screening type needs to be maintained. A combination of radiation & hormone therapy can be used as a remedy choice for moderate to high-risk localized PCa patients but the benefit is still not very clear in low-risk PCa patients. While using the combination therapy side effects should be managed efficiently and promptly.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals
2.
Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer
3.
Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT
4.
Year in Review: Non-Small Cell Lung Cancer
5.
Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries
1.
What Is Carboxyhemoglobin And How Can It Affect Your Health?
2.
Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment
3.
Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment
4.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
5.
The Importance of Having a Quick and Effective Heparin Antidote
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Navigating the Complexities of Ph Negative ALL - Part XVI
3.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation